KR20070057779A - 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조 - Google Patents
베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조 Download PDFInfo
- Publication number
- KR20070057779A KR20070057779A KR1020077002317A KR20077002317A KR20070057779A KR 20070057779 A KR20070057779 A KR 20070057779A KR 1020077002317 A KR1020077002317 A KR 1020077002317A KR 20077002317 A KR20077002317 A KR 20077002317A KR 20070057779 A KR20070057779 A KR 20070057779A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- formula
- alkyl
- aryl
- oac
- Prior art date
Links
- 0 CC(CC1)(C(C(*)C2)C1=*)C(C)(CC1*)C2C2(C)C1C(C)(C)[C@@](*)CC2 Chemical compound CC(CC1)(C(C(*)C2)C1=*)C(C)(CC1*)C2C2(C)C1C(C)(C)[C@@](*)CC2 0.000 description 13
- DGWVBOLRGRYBRU-UHFFFAOYSA-N CC(CCC=C(C)C)(C(CC1)C(C(C2)O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2=O)O Chemical compound CC(CCC=C(C)C)(C(CC1)C(C(C2)O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2=O)O DGWVBOLRGRYBRU-UHFFFAOYSA-N 0.000 description 2
- KVXMPQFKQBICKI-UHFFFAOYSA-N CC(CCC=C(C)C)(C(CC1)C(C(C2)OC(C)=O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2=O)O Chemical compound CC(CCC=C(C)C)(C(CC1)C(C(C2)OC(C)=O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2=O)O KVXMPQFKQBICKI-UHFFFAOYSA-N 0.000 description 1
- LKRKFHZNHGXEGW-XKBDXGRBSA-N CC(CCC=C(C)C)(C(CC1)C(C(C2)OC(C)=O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)[C@H]2O)O Chemical compound CC(CCC=C(C)C)(C(CC1)C(C(C2)OC(C)=O)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)[C@H]2O)O LKRKFHZNHGXEGW-XKBDXGRBSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58843304P | 2004-07-16 | 2004-07-16 | |
US60/588,433 | 2004-07-16 | ||
US10/961,346 | 2004-10-07 | ||
US10/961,346 US20060014704A1 (en) | 2004-07-16 | 2004-10-07 | Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production |
US10/963,214 US20060014729A1 (en) | 2004-07-16 | 2004-10-12 | Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production |
US10/963,214 | 2004-10-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20070057779A true KR20070057779A (ko) | 2007-06-07 |
Family
ID=35907856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077002317A KR20070057779A (ko) | 2004-07-16 | 2005-07-11 | 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1778715A2 (fr) |
JP (1) | JP2008506686A (fr) |
KR (1) | KR20070057779A (fr) |
CA (1) | CA2573699A1 (fr) |
MX (1) | MX2007000562A (fr) |
WO (1) | WO2006019685A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375097B1 (ko) | 2021-04-01 | 2022-03-17 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101397327B (zh) * | 2007-09-29 | 2012-01-11 | 广州天安医药科技有限公司 | 二氢人参皂苷Rg2的应用 |
CN104644658A (zh) * | 2013-11-22 | 2015-05-27 | 富力 | 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物 |
CN105753923B (zh) * | 2014-12-17 | 2017-09-29 | 富力 | 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用 |
KR101777920B1 (ko) | 2015-07-27 | 2017-09-14 | 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 | 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물 |
CN106046098B (zh) * | 2016-06-15 | 2017-07-11 | 大连大学 | 一种乙酰基人参皂苷Rd及其制备方法 |
CN113633650A (zh) * | 2021-08-26 | 2021-11-12 | 哈尔滨工业大学(威海) | 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用 |
CN115025106A (zh) * | 2022-07-12 | 2022-09-09 | 昆明理工大学 | 人参皂苷Rk3在制备具有神经保护作用药物中的用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3535588B2 (ja) * | 1994-11-18 | 2004-06-07 | 株式会社ネオス | ジンセノサイドRh2の製造方法 |
CA2301860C (fr) * | 1997-08-28 | 2009-05-26 | Cv Technologies Inc. | Standardisation chimique et pharmacologique des extraits de plantes medicinales |
WO2002007732A2 (fr) * | 2000-07-26 | 2002-01-31 | Cambridge University Technical Services Limited | Composes efficaces sur le plan pharmaceutique et utilisation associee |
KR100448667B1 (ko) * | 2001-04-25 | 2004-09-13 | (주) 디지탈바이오텍 | 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물 |
WO2004002494A1 (fr) * | 2002-05-16 | 2004-01-08 | Digital Biotech Co., Ltd. | Composition pour la prevention ou le traitement d'affections cerebrales degeneratives, comprenant un hydrolysat de ginsenosides |
KR20040036451A (ko) * | 2002-10-26 | 2004-04-30 | 한국과학기술연구원 | 진세노사이드 Rg3 또는 진세노사이드 Rh2를포함하는 글루타메이트 매개 신경독성 억제 조성물 |
KR20030088417A (ko) * | 2003-11-06 | 2003-11-19 | 주식회사 케이티앤지 | 인삼 모상근을 이용한 기억력 증강 신규조성물진세노-제이케이와 그 제조방법 |
-
2005
- 2005-07-11 JP JP2007521534A patent/JP2008506686A/ja active Pending
- 2005-07-11 KR KR1020077002317A patent/KR20070057779A/ko not_active Application Discontinuation
- 2005-07-11 CA CA002573699A patent/CA2573699A1/fr not_active Abandoned
- 2005-07-11 MX MX2007000562A patent/MX2007000562A/es not_active Application Discontinuation
- 2005-07-11 WO PCT/US2005/024533 patent/WO2006019685A2/fr active Application Filing
- 2005-07-11 EP EP05788885A patent/EP1778715A2/fr not_active Withdrawn
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102375097B1 (ko) | 2021-04-01 | 2022-03-17 | 주식회사 클로소사이언스 | 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
CA2573699A1 (fr) | 2006-02-23 |
WO2006019685A2 (fr) | 2006-02-23 |
WO2006019685A3 (fr) | 2006-06-15 |
MX2007000562A (es) | 2007-03-30 |
JP2008506686A (ja) | 2008-03-06 |
EP1778715A2 (fr) | 2007-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20070033977A (ko) | 알츠하이머병을 치료하고 베타-아밀로이드 펩티드 생성을저해하기 위한 화합물 | |
KR20070057779A (ko) | 베타-아밀로이드 펩티드 생산을 저해함으로써알츠하이머병을 치료하는 화합물 및 이들의 제조 | |
US9150608B2 (en) | Neuro-protective compounds and their use | |
US7507720B2 (en) | 5-Beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia | |
US20080207576A1 (en) | Substituted sapogenins and their use | |
CN101031580A (zh) | 通过抑制β-淀粉样肽生成治疗阿尔茨海默病的化合物和它们的制备 | |
US20020183294A1 (en) | Sapogenin derivatives and their use in the treatment of cognitive dysfunction | |
KR20090087075A (ko) | 신경변성 장애를 치료하는데 유용한 화합물 | |
Sy et al. | Identification of “sarsasapogenin-aglyconed” timosaponins as novel Aβ-lowering modulators of amyloid precursor protein processing | |
Kou et al. | Neuroprotective effects of a new triterpenoid from edible mushroom on oxidative stress and apoptosis through the BDNF/TrkB/ERK/CREB and Nrf2 signaling pathway in vitro and in vivo | |
US20030100542A1 (en) | 5-hydroxysapogenin derivatives with anti-dementia activity | |
Zhang et al. | Evaluation of structure–activity relationships of ginsenosides against amyloid β induced pathological behaviours in transgenic Caenorhabditis elegans | |
Mutoh et al. | Abnormal cross‐talk between mutant presenilin 1 (I143T, G384A) and glycosphingolipid biosynthesis | |
US9775856B2 (en) | C-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of Genista tenera ethyl acetate extracts containing some of those agents | |
KR102141656B1 (ko) | 글루코실트랜스퍼라제를 이용한 코르티코스테론의 생물 전환 방법 및 이로부터 얻어진 코르티코스테론 글루코시드 | |
KR102374047B1 (ko) | N,N′-디아세틸-p-페닐렌디아민 화합물을 유효성분으로 포함하는 알츠하이머병 예방, 개선 또는 치료용 조성물 | |
US20170348340A1 (en) | New c-glycosylpolyphenol antidiabetic agents, effect on glucose tolerance and interaction with beta-amyloid. therapeutic applications of the synthesized agent(s) and of genista tenera ethyl acetate extracts containing some of those agents | |
Abdel-Kader | Molecular and cellular mechanisms of Ginkgo biloba extract [EGb 761] in improving age-related and β-amyloid [beta-amyloid] induced neuronal dysfunctions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |